Gene Technos Science Co. shareholders have approved to make Cell Technology, acquired in January 2019, a wholly-owned subsidiary. Cell Technology has a partnership with over 2000 medical institutions across Japan to provide services for dental pulp-derived and other stem cells. It supplies such cells to companies such as Daiichi Sankyo, Eisai, Nikon and Sekisui for research and GeneTechnoscience is preparing to develop this product line further into cell therapeutics. JCR Pharma and Teijin have already implemented Phase I/II clinical tests of dental pulp-derived stem cells for the treatment of acute cerebral infarction in Japan.

Gene Techno Science news release, March 12, 2019

Nikkei Biotech news release, March 15, 2019